Mannkind Corp. (MNKD)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 899460 · fiscal year ends in Dec
Closing price $3.50 on 29 Oct 2026; 52-week range $2.28 to $6.21.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $393.6M
- Revenue growth
- 30.5%
- Net income, last twelve months
- -$43.6M
- Earnings per share
- -$0.13
- Gross margin
- 89.8%
- Operating margin
- 2.3%
- Net margin
- -11.1%
- Free cash flow
- -$18.1M
- Market value
- $1.1B
- Cash
- $52.9M
- Debt
- $319.1M
- Shares outstanding
- 309.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $349.0M | $38.8M | $5.9M | $0.02 | $13.7M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $285.5M | $72.6M | $27.6M | $0.10 | $32.8M | 10-K filed 26 Feb 2025 |
| FY2023 | 31 Dec 2023 | $199.0M | $8.7M | -$11.9M | -$0.04 | -$8.3M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $99.8M | -$64.1M | -$87.4M | -$0.34 | -$88.3M | 10-K filed 23 Feb 2023 |
| FY2021 | 31 Dec 2021 | $75.4M | -$47.0M | -$80.9M | -$0.32 | -$73.2M | 10-K filed 24 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $109.4M | -$19.0M | -$0.06 |
| Q1 FY2026 | 31 Mar 2026 | $90.2M | -$16.6M | -$0.05 |
| Q4 FY2025 | 31 Dec 2025 | $112.0M | -$15.9M | -$0.05 |
| Q3 FY2025 | 30 Sep 2025 | $82.1M | $8.0M | $0.03 |
| Q2 FY2025 | 30 Jun 2025 | $76.5M | $668.0K | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $78.4M | $13.2M | $0.04 |
| Q4 FY2024 | 31 Dec 2024 | $76.8M | $7.4M | $0.03 |
| Q3 FY2024 | 30 Sep 2024 | $70.1M | $11.6M | $0.04 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Royalties | $128.1M | 36.3% |
| AFREZZA product sales | $114.1M | 32.3% |
| Collaborations and services | $106.7M | 30.2% |
| Services | $4.3M | 1.2% |
Company events
The newest 8-K filings of 288 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 21 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Jul 2026 | 8-K | Share sale, Other events | 3.02, 8.01, 9.01 |
| 2 Jun 2026 | 8-K | Other events | 8.01 |
| 28 May 2026 | 8-K | Other events | 8.01 |
| 22 May 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Nov 2025 | 8-K | Other events | 8.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 9 Oct 2025 | 8-K | Deal completed, Material agreement, New debt | 1.01, 2.01, 2.03, 9.01 |
| 27 Aug 2025 | 8-K | Material agreement | 1.01, 9.01 |
Every filing
The newest filings with the SEC of 539 held.
| Filed | Form | Period |
|---|---|---|
| 21 Aug 2026 | 8-K | 21 Aug 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 24 Jul 2026 | 8-K | 23 Jul 2026 |
| 2 Jun 2026 | 8-K | 29 May 2026 |
| 28 May 2026 | 8-K | 27 May 2026 |
| 22 May 2026 | 8-K | 20 May 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 7 Apr 2026 | ARS | 31 Dec 2025 |
| 7 Apr 2026 | DEFA14A | – |
| 7 Apr 2026 | DEF 14A | 7 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 25 Sep 2026 | Binder Steven B., Director | Sale under a trading plan | 39,051 | $3.29 | $128.5K | 713,258 | 28 Sep 2026 |
| 10 Sep 2026 | Binder Steven B., Director | Sale under a trading plan | 33,558 | $3.81 | $127.9K | 752,309 | 14 Sep 2026 |
| 7 Aug 2026 | Binder Steven B., Director | Sale under a trading plan | 39,051 | $4.06 | $158.5K | 785,867 | 10 Aug 2026 |
| 17 Jul 2026 | Thomson David, EVP Genl Counsel & Secretary | Sale under a trading plan | 24,109 | $4.05 | $97.6K | 797,554 | 17 Jul 2026 |
| 17 Jul 2026 | Binder Steven B., Director | Sale under a trading plan | 52,485 | $4.06 | $213.1K | 824,918 | 17 Jul 2026 |
| 20 May 2026 | Consiglio Ronald J, Director | Took pay in stock | 16,556 | – | – | – | 22 May 2026 |
| 20 May 2026 | Hooper Anthony C, Director | Took pay in stock | 16,556 | – | – | – | 22 May 2026 |
| 20 May 2026 | Shannon James Samuel, Director | Took pay in stock | 16,556 | – | – | – | 22 May 2026 |
| 12 May 2026 | Binder Steven B., Director | Sale under a trading plan | 16,940 | $3.29 | $55.7K | 808,008 | 13 May 2026 |
| 12 May 2026 | Thomson David, EVP Genl Counsel & Secretary | Sale under a trading plan | 3,033 | $3.29 | $10.0K | 826,299 | 13 May 2026 |
| 10 Mar 2026 | Castagna Michael, Chief Executive Officer | Purchase | 100,000 | $2.59 | $259.0K | 2,575,911 | 10 Mar 2026 |
| 8 Jan 2026 | Tross Stuart A, Chief People & Workpl Officer | Sale under a trading plan | 47,006 | $6.33 | $297.5K | 985,007 | 9 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 25 Sep 2026 | STEVEN BINDER, Director | 39,051 | $128.5K | 25 Sep 2026 |
| 10 Sep 2026 | STEVEN BINDER, Director | 33,558 | $132.2K | 10 Sep 2026 |
| 7 Aug 2026 | STEVEN BINDER, Director | 39,051 | $151.9K | 7 Aug 2026 |
| 17 Jul 2026 | DAVID THOMSON, Officer | 24,109 | $97.4K | 17 Jul 2026 |
| 17 Jul 2026 | STEVEN BINDER, Director | 52,485 | $212.0K | 17 Jul 2026 |
| 12 May 2026 | DAVID THOMSON, Officer | 10,113 | $34.0K | 12 May 2026 |
| 12 May 2026 | STEVEN BINDER, Director | 16,940 | $56.9K | 12 May 2026 |
| 8 Jan 2026 | STUART A TROSS, Officer | 47,000 | $297.5K | 8 Jan 2026 |
| 12 Dec 2025 | MICHAEL CASTAGNA, Director, Officer | 107,920 | $627.0K | 12 Dec 2025 |
| 2 Dec 2025 | MICHAEL CASTAGNA, Director, Officer | 107,920 | $586.0K | 2 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Rubric Capital Management LP | 13G | 5.83% | 18.0M |
| 31 Jul 2026 | Vanguard Capital Management | 13G | 5% | 15.5M |
| 12 May 2026 | STATE STREET CORPORATION | 13G | 6.1% | 18.7M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 25.5M | -2.6% | 5.06 |
| 30 Sep 2026 | 26.2M | -11.02% | 4.44 |
| 15 Sep 2026 | 29.4M | +10.71% | 9.08 |
| 31 Aug 2026 | 26.6M | -7.09% | 8.48 |
| 14 Aug 2026 | 28.6M | +2.46% | 5.61 |
| 31 Jul 2026 | 27.9M | -1.05% | 6.24 |
| 15 Jul 2026 | 28.2M | +7.65% | 5.85 |
| 30 Jun 2026 | 26.2M | -16.21% | 4.41 |
Funds that hold it
From each fund's latest Form 13F.
301 funds held it at 30 Jun 2026: 140 added and 61 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 32,133,223 | $136.9M | +3,532,225 |
| Rubric Capital Management LP | 18,000,000 | $76.7M | +14,379,587 |
| State Street Corp. | 16,174,043 | $68.9M | -2,509,440 |
| Vanguard Capital Management LLC | 13,169,392 | $56.1M | +278,326 |
| Geode Capital Management, LLC | 7,947,203 | $33.9M | +442,056 |
| Wellington Management Group LLP | 7,844,807 | $33.4M | +4,561,628 |
| Frazier Life Sciences Management, L.P. | 6,600,000 | $28.1M | +700,000 |
| Deep Track Capital, LP | 6,000,000 | $25.6M | +6,000,000 |
| 180 Wealth Advisors, LLC | 4,959,351 | $21.1M | +667,648 |
| FMR LLC | 4,101,046 | $17.5M | +620,082 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B